America’s leadership in drug innovation is eroding as pharmaceutical companies increasingly source new compounds from China, former FDA Commissioner Scott Gottlieb warns in STAT. In 2024, one-third of all new drugs licensed by U.S. firms originated in Chinese labs — a stark contrast to five years ago, when that number was zero.
This item is available in full to subscribers.
To continue reading, you will need to either log in to your subscriber account, below, or purchase a new subscription.
If you are a current subscriber, and had an account on our previous site, you already have an account. If you have not yet logged into our new site, click here to reset your password.
Otherwise, click here to view your options for subscribing.
Please log in to continue |
